Bot Chart, page-11652

look whatever it is, it has to be bigger than the Japan sales results. Overall US has a substantially higher population and works already been done to ensure this is available via 3rd party processing company..I forget their name.

I think the territory deals in Japan, soon Korea and then other countries to be added might eventually make up 2m - 5m in revenue alone per year. I envision that once FDA approve, Europe won't be too far behind adding even more to this. I think they prefer to do licensing deals for anywhere outside the US taking the risk away and will enable them to work on other pipeline stuff.

It's really a waiting game for the moment but based on the milestones that have to be hit for the directors to get their payments in shares/bonuses - it seems well within their capabilities to hit these targets otherwise they wouldn't have put such targets in place.

0.20 will eventually fall - it's just a matter of time and then it will run to 0.29